Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FIT-PIV trial of ELGN-2112 in preterm infants with intestinal malabsorption
jRCT2031260282Recruiting
- Sponsor
- Elgan Pharma
- Start
- Sep 2026
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
01
Overview
Randomised, double-blind trial in intestinal malabsorption comparing ELGN-2112 with Placebo (2 arms). Primary endpoint: Number of days to achieve full enteral feeding. Started Sep 2026; status: recruiting.
02
Drugs
elgn-gi
03
Conditions
intestinal malabsorption
Beyond the preview
Go deeper on jRCT2031260282.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031260282.